From Cytokine Endotypes to Clinical Reality in Still’s Disease Recent EULAR 2026 data highlight a paradigm shift in Still’s disease from syndromic management to biologically informed precision therapy. https://t.co/fBtkDLPJNE https://t.co/y8NBW6VHHa

• From Cytokine Endotypes to Clinical Reality in Still’s Disease | RheumNow

Genicular artery embolization (GAE) in knee OA? Multiple open label studies & metanalyses suggest a clear pain benefit; BUT 3 sham-controlled RCTs have not demonstrated a statistically significant benefit over placebo. GAE is not addressed by ACR or EULAR guidelines. https://t.co/amIN6kzY74

From BiTE to TriTE: Progress of T-cell Engagers in RMDs At EULAR 2026 in London, T-cell engagers drew attention as a strategy to achieve deep B-cell depletion and drug-free remission in refractory RMDs. BiTEs offer off-the-shelf availability, reversible toxicity from short https://t.co/jjXrf9tcaA

How many CAR-T’s do we need to test drive? There were 93 abstracts with CAR-T in title at #EULAR2026! Additionally, there was an excellent review (WIN) by Dr. Hector Chinoy. We know lots but have more questions. https://t.co/dGpfffaubX https://t.co/3MS1ZjQExj

• How many CAR-T’s do we need to test drive? | RheumNow

Single center study of 102 pts starting JAK inhibitor (72% >50yrs; 77% RA) shows only 27.5% received at least one RZV vaccination dose (Shingrix) & only 3 recv RZV within 30 daysof a JAK inhibitor. ????? (I vaccinate everyone going on a JAKi w/ Shingrix - don't you?) https://t.co/7HUqGGBeJ8

MTX: SC vs Oral? Metanalysis of 9 RCTs, 974 RA pts. Compared w/ oral, SC MTX signif. incr odds of ACR20 (RR=1.15), ACR50 (RR=1.14) & reduced GI adverse events (RR=0.58), diarrhea (RR=0.42): BUT no difference in ACR70, DAS28-ESR, bioavailability AUC, or other AE https://t.co/54xVnerRuS

Missed a session at EULAR 2026? No problem. The RheumNow Faculty Reporter team was on the ground covering the studies, debates, and breakthroughs that are shaping the future of rheumatology. From JAK safety and CAR-T therapies to advances in lupus, psoriatic arthritis, and ILD, https://t.co/cKmhq8mAIf

Late-breaking abstracts presented at EULAR addressed a wide range of clinical concerns and suggested that patients and clinicians have much to look forward to in coming months and years. https://t.co/m04h8eI3ZM https://t.co/HOQNA5gc6k

• Late-Breaking Studies at EULAR 2026 | RheumNow

EULAR 2026 Recommendations on PMR, GCA, and Takayasu Arteritis On the final day of EULAR, Mukhtyar et al (on behalf of a large international task force) presented the updated EULAR recommendations for management of PMR, GCA, and TAK. There were 5 overarching principles and 12 https://t.co/kpykylEbsr

The North American Expert Consensus on ASCVD Screening in Lupus Nephritis Drs. Sheila Reyes and Shivani Garg discuss abstract OP094, presented in London at the EULAR 2026 Congress https://t.co/Vm2QFlO3fL https://t.co/4Xp9tkubLh

• The North American Expert Consensus on ASCVD Screening in Lupus Nephritis | Rhe…

Usual testing for SSA (Ro) pos. in Sjogrens identifies both Ro52 + Ro60 Abs, found in 70% of SjD. Pts who are double pos (Ro52+Ro60) have more severe dz, more Bcell activity. Ro60+ have milder dz; Recent report shows SjD pts have Ro60-specific CD4 T cells, activating Bcells https://t.co/SqoLICHOkS